Medicine and Dentistry
Sickle Cell Retinopathy
100%
Optical Coherence Tomography
51%
Optical Coherence Tomography Angiography
46%
Sickle-Cell Disease
43%
Visual Acuity
35%
Retinopathy
34%
Fluorescein Angiography
28%
Capillary
26%
Sickle Cell
23%
Uveitis
22%
Spectral Domain Optical Coherence Tomography
21%
Odds Ratio
18%
Retinal Imaging
16%
Agents Acting on the Eye
15%
Fundus Photography
15%
Macular Edema
15%
Steroid Treatment
15%
Retinal Detachment
15%
Maculopathy
14%
Choroidal Neovascularization
14%
Diabetic Retinopathy
14%
Wet Macular Degeneration
13%
Bleeding
12%
Best Corrected Visual Acuity
12%
Glaucoma
12%
Vitrectomy
12%
Bevacizumab
12%
Multimodal Imaging
11%
Age Related Macular Degeneration
11%
Surgery
10%
Visual Impairment
10%
Vision
10%
Patient with Sickle Cell Disease
10%
Angiography
10%
Photograph
9%
Vasculotropin
9%
Vitreous Hemorrhage
9%
Dilated Fundus Examination
8%
Clinical Examination
8%
Eye Disease
7%
Fluocinolone Acetonide
7%
Surgical Technique
7%
Hemoglobinopathy
6%
Diagnosis
6%
Vitreous
6%
Disease
6%
Retinal Blood Vessel
6%
Macular Hole
6%
Blood Flow
6%
Biological Marker
6%
Keyphrases
Sickle Cell Retinopathy
53%
Sickle Cell Disease
39%
Proliferative Sickle Cell Retinopathy
25%
Optical Coherence Tomography Angiography (OCT-A)
24%
United States
18%
Best-corrected Visual Acuity
17%
Visual Acuity
16%
Ultra-widefield Fluorescein Angiography
16%
Retinal Vein Occlusion
15%
Confidence Interval
15%
Self-reported Vision
15%
Neovascularization
13%
Macular Edema
13%
Odds Ratio
13%
Ischemic Index
12%
Neovascular Age-related Macular Degeneration (nAMD)
10%
Genotype
10%
Ozurdex
10%
Vision Impairment
10%
Vision Loss
10%
Retinopathy
10%
Superficial Capillary Plexus
8%
Myopic Choroidal Neovascularization (mCNV)
8%
Foveal Avascular Zone
8%
Optical Coherence Tomography
8%
Anti-VEGF Therapy
8%
Deep Capillary Plexus
8%
Treatment Burden
7%
Ultra-high Field
7%
Intravitreal Bevacizumab
7%
Sickle Cell Maculopathy
7%
OCT Angiography
7%
Clinical Examination
7%
Macular
7%
Edema
7%
Vitrectomy
7%
Flow Loss
6%
HbSS
6%
Diabetic Macular Edema
6%
Bevacizumab
6%
Vitreous Hemorrhage
6%
Retinal Neovascularization
6%
Microvascular Changes
6%
Age-related Macular Degeneration
6%
Uveitis
6%
Panuveitis
6%
Inflammation
6%
Posterior Segment
6%
Retinal Microvasculature
6%
Retinal Thickness
5%